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ABSTRACT 17 
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most threatening 18 
microorganisms for global human health. The current strategies to reduce the impact of S. 19 
aureus include a restrictive control of worldwide antibiotic use, prophylactic measures to 20 
hinder contamination and the search for novel antimicrobials to treat human and animal 21 
infections caused by this bacterium. The latter strategy is currently the focus of considerable 22 
research. In this regard, phage lytic proteins (endolysins and virion-associated peptidoglycan 23 
hydrolases, VAPGHs) have been proposed as suitable candidates. Indeed, these proteins 24 
display narrow-spectrum antimicrobial activity and a virtual lack of bacterial resistance 25 
development. Additionally, the therapeutic use of phage lytic proteins in S. aureus animal 26 
infection models is yielding promising results, showing good efficacy without apparent side 27 
effects. Nonetheless, human clinical trials are still in progress and data are not available yet. 28 
This review also analyzes the main obstacles for introducing phage lytic proteins as human 29 
therapeutics against S. aureus infections. Besides the common technological problems 30 
derived from large-scale production of therapeutic proteins, a major setback is the lack of a 31 
proper legal framework regulating their use. In that sense, the competent health authorities 32 
should urgently have a timely discussion about these new antimicrobials. On the other hand, 33 
the research community should provide data to dispel any doubts regarding their efficacy and 34 
safety. Overall, the appropriate scientific data and regulatory framework will encourage 35 
pharmaceutical companies to invest in these promising antimicrobials. 36 
 37 
 38 
INTRODUCTION 39 
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Staphylococcus aureus is one of the most important human pathogens, causing a variety of 40 
diseases (skin, soft tissue, wound, bone and bloodstream infections, toxic shock syndrome 41 
and food poisoning). This bacterium has become a serious threat in hospitals, as it is one of 42 
the most common causes of nosocomial infections. Moreover, the emergence and increase in 43 
antibiotic resistance (especially methicillin resistance) in clinical environments is really 44 
worrying. Recent data from the World Health Organization (WHO) indicate that methicillin-45 
resistant S. aureus (MRSA) strains are responsible for more than 20% of all infections in 46 
WHO regions, but this percentage can reach 80% in some countries (1). 47 
Additionally, S. aureus is one of the major causative agents of foodborne diseases in humans 48 
due to the production of enterotoxins (2). In 2014, consumption of food products 49 
contaminated with S. aureus was responsible for 7.5% of all foodborne outbreaks in the EU 50 
(3). The presence of MRSA in farm animals is also a serious concern, since animals can 51 
acquire and disseminate strains other than the livestock-associated MRSA (LA-MRSA) (4). 52 
It is well known that the widespread use of antibiotics in food animal production has favored 53 
the increase in multidrug resistant bacteria (MDR) that led to the current global health crisis 54 
(5, 6). To cope with this problem, several countries have restricted the use of antimicrobials 55 
in animal farming (e.g. growth promoters and disease prevention compounds) (7). 56 
Bacteriophages, or phages, are viruses that exclusively infect bacteria to carry out their life 57 
cycle (Fig. 1A). In most cases, the lytic life cycle ends up with the death of the bacterial cell, 58 
thereby making phages the natural killers of bacteria. Lysis can proceed by one of two basic 59 
mechanisms. On the one hand, single-stranded genome phages encode a lysis effector, which 60 
inhibits biosynthesis of bacterial peptidoglycan. In contrast, release of the phage progeny in 61 
dsDNA phages is mediated by two proteins, holin and endolysin, which are responsible for 62 
cell-envelope disruption. Once the lytic life cycle has been completed and the virion particles 63 
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are mature inside the bacterial cell, the holin forms pores in the inner cell membrane allowing 64 
access of the endolysin to the cell wall. Subsequently, endolysin molecules degrade 65 
peptidoglycan, which is followed by osmotic lysis of the cell (Fig. 1A and B). In addition, 66 
several phages can use the host cell secretion machinery (Sec system) to release their 67 
endolysins, and also encode a holin (pinholin) involved in proton-motive force dissipation to 68 
activate the secreted endolysin. Phages infecting Gram-negative hosts are provided with 69 
additional proteins named spanins that help to break the outer membrane (8). 70 
Virion-associated peptidoglycan hydrolases (VAPGHs) are structural components of the 71 
virion particle and participate in the initial steps of infection by slightly degrading 72 
peptidoglycan to allow entry of the phage genetic material into the bacterial cell (Fig. 1A and 73 
B). Both types of lytic proteins, endolysins and VAPGHs, are useful as antimicrobials due to 74 
their potential for degrading peptidoglycan resulting in cell lysis when added exogenously. 75 
Recently, there has been a renewed interest in studying and exploiting the potential of phages 76 
and phage lytic proteins to combat undesirable bacteria (9-11). Additionally, phages can be 77 
used as tools for multiple health-related applications, including vaccine development, gene 78 
delivery and bacterial detection (12). 79 
In this context, this review aims to present and analyze the main advantages of phage lytic 80 
proteins to combat S. aureus in balance with the main obstacles that interfere with their 81 
commercialization.  82 
 83 
1. MAIN CHARACTERISTICS AND PROPERTIES OF S. aureus PHAGE 84 
LYTIC PROTEINS 85 
1.1. Structure and enzymatic activity 86 
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All phage lytic proteins (endolysins and VAPGHs) encoded by S. aureus bacteriophages have 87 
a modular structure, a common trait displayed by endolysins from Gram-positive dsDNA 88 
phages (13). This modular organization in distinct functional domains provides phage lytic 89 
proteins with two useful properties. On the one hand, this structure confers remarkable 90 
substrate specificity (further explained at the end of this section) and, on the other hand, it 91 
allows performing protein engineering in order to design new proteins with enhanced 92 
antimicrobial activity (see section 1.2). 93 
Most staphylococcal phage endolysins possess one or two N-terminal catalytic domains and 94 
one C-terminal cell wall binding domain (CBD). Interestingly, no signal peptides or 95 
transmembrane domains have been described in staphylococcal phage endolysins. A similar 96 
modular structure was described for VAPGHs, consisting of one or two catalytic domains, 97 
although these proteins always lack a known CBD (11) (Fig. 2B). 98 
In order to understand the catalytic activity of phage lytic proteins, it is important to look at 99 
the structure of their enzymatic target: bacterial peptidoglycan, which consists of linear 100 
glycan strands cross-linked by short peptides. These glycan strands are made up of alternating 101 
N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues linked by -102 
1,4 glycosidic bonds. The D-lactoyl group of each MurNAc residue is substituted by a peptide 103 
stem whose composition in S. aureus is L-Ala-D-Glu-L-Lys-D-Ala. Cross-linking of the 104 
glycan strands generally occurs between the carboxyl group of D-Ala at position 4 and the 105 
amino group of the di-amino acid at position 3, through a short peptide bridge composed of 106 
five Gly residues (14) (Fig. 2B). 107 
The catalytic domains of phage lytic proteins are classified into 6 different types according 108 
to their enzymatic activity against peptidoglycan: N-acetylmuramoyl-L-alanine amidases, 109 
interpeptide bridge endopeptidases, L-alanoyl-D-glutamate endopeptidases, N-acetyl-β-D-110 
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muramidases, transglycosylases and N-acetyl-β-D-glucosaminidases (Fig. 2B). On the one 111 
hand, lysozymes (or muramidases) and transglycosylases cleave the N-acetylmuramoyl- β -112 
1,4-N-acetyl-glucosamine bond, whilst glucosaminidases and amidases hidrolyze the N-113 
acetylglucosaminyl β -1,4-N-acetylmuramine bond and the amide bond between the sugar 114 
and the peptide moieties, respectively. Finally, endopeptidases cleave the bond within the 115 
interpeptide bridge. 116 
Endolysins from staphylococcal phages rarely contain transglycosylases. Instead, the 117 
catalytic domains found in these proteins are LYSO (phage_lysozyme domain), PET-M23 118 
(peptidase domain M23), AMI-2 (amidase_2 domain), AMI-3 (amidase_3 domain), and 119 
CHAP (cysteine-, histidine-dependent amidohydrolase/peptidase), with CHAP being the 120 
most frequent domain (>74%) (13). 121 
Regarding CBDs, endolysins derived from phages infecting S. aureus usually contain SH3-122 
related domains (PF08460), with SH3_5 and SH3b being the most common (13, 15) (Fig. 2). 123 
SH3b domains have been shown to bind to the peptidoglycan peptide cross-bridge (16). 124 
However, there are some endolysins derived from phages phiNM3, phi13 and MW1 where 125 
the CBD showed no homology to SH3b (17). These authors postulated that the phiNM3 CBD 126 
could bind to cell-wall associated carbohydrates instead of the pentaglycine peptide cross-127 
bridge. More recently, a new type of CBD has been described in the endolysin of phage SA97 128 
(LysSA97), which only shares 19% homology with other staphylococcal endolysins 129 
deposited in databases (18). 130 
Most phage endolysins possess high specificity against the genus or species infected by the 131 
phage from which they derive, which represents a notable advantage over classical wide 132 
spectrum antibiotics. Nonetheless, the interaction of these proteins with their substrate at the 133 
molecular level is not fully understood, so it is still not clear which fragment of the molecule 134 
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determines specificity. There is limited data regarding the role of the catalytic domains in the 135 
specificity of endolysins. For example, fusion of catalytic domains from the endolysin 136 
encoded by Streptococcus agalactiae bacteriophage B30 to a CBD specific for S. aureus 137 
strains can expand the lytic activity of the chimeric protein to S. aureus (19). This suggests 138 
that catalytic domains do not exert strict specificity. Regarding CBDs, Becker et al. (2009) 139 
showed that a chimeric protein consisting of the LysK SH3b domain and the streptococcal 140 
endolysin λSa2 catalytic domain exhibited both staphylolytic and streptolytic activity (15). 141 
Therefore, the specificity of endolysins might result from the combined interaction of 142 
catalytic and binding domains with species-specific cell wall receptors in the peptidoglycan 143 
structure, which remain unknown to date. Indeed, analysis of the crystal tridimensional 144 
structure of the individual domains might be useful for revealing this interaction and to design 145 
site-directed mutants with altered activity or substrate specificity (20, 21). 146 
 147 
1.2. Design of chimeric proteins 148 
The development of phage lytic proteins as novel antimicrobials entails systematic mining of 149 
naturally occurring proteins, as well as design of new ones. This process is greatly facilitated 150 
by the modular structure of staphylococcal phage lytic proteins. Indeed, this organization 151 
allows exploring domain deletion and shuffling as a route to obtain new endolysins with 152 
enhanced properties (Fig. 3). Some of the strategies used in the design of new lytic proteins 153 
include synthesis of truncated proteins, such as those containing only one catalytic domain 154 
or one CBD, and production of new chimeric enzymes by combining domains from different 155 
lytic proteins. Thus, studies involving truncated proteins have demonstrated that enzymes 156 
containing just the CHAP domain of the parental endolysin generally display a slight increase 157 
in activity, whereas those containing only the amidase domain frequently have no lytic 158 
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activity (22-24). Interestingly, the design of chimeric proteins has shown good results 159 
regarding the development of improved lytic proteins. For instance, a chimeric protein based 160 
on LysK, PRF-119, was obtained by fusing the CHAP domain from LysK to the SH3b 161 
domain from lysostaphin (25). PRF-119 displayed very good activity (i.e.  the MIC90 was 162 
0.391 µg/ml for both MRSA and MSSA strains). Another example is a derivative of 163 
endolysin Ply187 containing the CHAP domain fused to the SH3b CBD of endolysin LysK, 164 
which exhibited a 10-fold increase in specific activity compared with the truncated protein 165 
carrying the individual CHAP domain (26). Similar results were obtained in studies that 166 
analyzed whether the presence of more catalytic domains in a single endolysin molecule leads 167 
to a higher activity. To test this hypothesis, chimeric proteins containing three catalytic 168 
domains plus one CBD were obtained by fusing the two LysK catalytic domains with the 169 
complete lysostaphin molecule. Unexpectedly, the resulting proteins showed intermediate 170 
activity compared with the respective parental proteins (i.e. the MIC values for S. aureus 171 
USA100 were 14 µg/ml and 20 µg/ml for the chimeric proteins K-L and L-K, respectively, 172 
which are between those determined for lysostaphin (1.2 µg/ml) and LysK (96 µg/ml) (29). 173 
Finally, an important step forward in the study of chimeric proteins against S. aureus was the 174 
modification of phage lytic proteins to kill intracellular S. aureus. This was achieved by using 175 
a protein transduction domain (PTD) composed of a short cationic peptide sequence that 176 
facilitates crossing of the eukaryotic membrane by the lytic protein. The same study also 177 
showed that lysostaphin requires the presence of a PTD for the eradication of intracellular S. 178 
aureus. However, some chimeric proteins derived from LysK and lysostaphin did not require 179 
this domain to enter cultured bovine mammary cells (29). 180 
From all these data, we can conclude that domain shuffling is a powerful tool for increasing 181 
the activity of phage lytic proteins. Of note, it has been widely proven that CHAP domains 182 
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from S. aureus phage lytic proteins possess higher activity than other types of catalytic 183 
domains, at least under in vitro conditions (22-24). Moreover, the addition of a CBD to an 184 
individual CHAP domain significantly increases its in vitro activity. 185 
 186 
1.3. Anti-biofilm activity 187 
One of the main obstacles for the eradication of S. aureus in hospitals and food industries is 188 
its ability to form biofilms. These structures are the most common lifestyle of bacteria in 189 
nature. S. aureus is not an exception, and most strains show a variable ability to adhere to 190 
and grow on several biotic and abiotic surfaces (30). Worryingly, biofilms represent a barrier 191 
to the action of antibiotics and disinfectants, hindering both the treatment of infections and 192 
the cleaning of surfaces. In this context, there is considerable evidence regarding the efficacy 193 
of phage lytic proteins against preformed S. aureus biofilms. Some of the proteins with 194 
proven anti-biofilm properties are endolysins SAL-2, phi11, PlyGRCS, SAL200, as well as 195 
the chimeric proteins CHAPK (derived from LysK), ClyH (derived from Ply187 and phiNM3 196 
endolysins) and ClyF (derived from Ply187 and PlySs2 endolysins) (31-37). In the case of 197 
the chimeric protein ClyH, the susceptibility of biofilms turned out to be dependent on the 198 
strain and the biofilm maturation stage. Thus, removal of 72 h-old biofilms needed a longer 199 
treatment than 24 h- and 48 h-old biofilms, probably due to the presence of a greater amount 200 
of extracellular material (31). However, complete removal of adhered cells in biofilms is not 201 
easy to achieve by using phage lytic proteins. To solve this problem, some authors have 202 
proposed the use of two consecutive rounds of treatment (38) and/or the combination with 203 
antibiotics. For instance, treatment of S. aureus biofilms with minocycline followed by 204 
treatment with endolysin MR-10 can significantly reduce both young and mature biofilms 205 
formed by MRSA (39). The main advantage of endolysins as anti-biofilm agents compared 206 
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to traditional antibiotics is their ability to lyse bacteria even when they are not actively 207 
growing. In addition, endolysin LysH5 was proven to be also active against persister cells, 208 
which also contribute to the recalcitrant nature of biofilms (38).  209 
The development of products based on phage proteins to eliminate bacterial biofilms requires 210 
accurate quantification of the anti-biofilm activity exhibited by different proteins. Indeed, 211 
such a technique is of paramount importance to select those proteins that display the highest 212 
activity. Recently, a method that measures biofilm formation and development in real time 213 
was validated to establish the anti-biofilm activity of phage lytic proteins. This method relies 214 
on changes in the impedance signals caused by S. aureus when attaching and detaching after 215 
protein treatment (40). 216 
Besides biofilm eradication, phage lytic proteins can also be useful for the inhibition of 217 
biofilm development. For instance, a feasible strategy that can be applied in the near future 218 
to prevent the attachment of S. aureus to surfaces is manufacturing antimicrobial surfaces 219 
coated with endolysins. In fact, lytic proteins can be attached to silica nanoparticles (SNPs) 220 
to facilitate surface incorporation or embedded into films of poly hydroxyethyl methacrylate, 221 
which already showed efficacy against Listeria (41). 222 
 223 
1.4. Bacterial resistance and adaptive responses 224 
In addition to exhibiting high antibacterial activity, a good antimicrobial agent should 225 
preferably not select for bacterial resistance. To date, data about the emergence of resistance 226 
to endolysins in bacteria belonging to different genera indicate that resistance acquisition is 227 
quite rare or even nonexistent. Undoubtedly, this is one of the most valuable characteristic of 228 
endolysins, and could be linked to the fact that their targets in the peptidoglycan molecule 229 
are essential for bacterial viability and fitness. As a result, mutations leading to endolysin 230 
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resistance would be too harmful for the bacterial cell (42). Moreover, most S. aureus 231 
endolysins contain two catalytic domains, which theoretically would reduce the probability 232 
of finding bacteria with a double modification in the target structures. There have been 233 
several attempts to study the acquisition of resistance to phage lytic proteins in S. aureus, 234 
although no resistant bacteria were detected (43, 44). More recently, it has been described 235 
that sub-lethal exposure of S. aureus to LysK in liquid medium yielded cultures with a 42-236 
fold increase in the MIC, while exposure in solid medium only resulted in a 2-fold increase 237 
in resistance (29). By contrast, S. aureus cells exposed to chimeric proteins formed by three 238 
catalytic domains (two catalytic domains from LysK fused to lysostaphin) hardly showed any 239 
increase in resistance. Indeed, the chimeric proteins K-L and L-K yielded cultures with 8-240 
fold and 2-fold increase in MIC, respectively, after exposure in liquid medium, whereas 241 
exposure in solid medium did not lead to a detectable increase in resistance (29). These 242 
observations support the importance of designing new chimeric proteins to improve the 243 
properties of natural endolysins and VAPGHs. In general, bacterial resistance development 244 
against phage lytic proteins is lower than that obtained for traditional antibiotics, although 245 
the frequency under in vivo conditions has not been determined yet. Besides resistance 246 
development, a recent study has evaluated the transcriptional response of S. aureus cells 247 
exposed to sub-inhibitory concentrations of phage lytic proteins. This study revealed that 248 
endolysin LysH5 and the VAPGH-derived chimeric protein CHAPSH3b led to the 249 
downregulation of genes encoding different proteins with autolytic activity (45). The authors 250 
linked these transcriptional changes to a decrease in biofilm formation, as the major autolysin 251 
AtlA is an important factor in early stages of biofilm development. This would reinforce the 252 
usefulness of lytic proteins as anti-biofilm compounds. Interestingly, this article also showed 253 
that deletion of the autolysin-encoding gene leads to low-level resistance to the two lytic 254 
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proteins. This suggests that the gene expression changes triggered by lytic proteins may 255 
confer some degree of adaptive resistance against these antimicrobials and, therefore, it 256 
would deserve to be evaluated before the extensive use of these proteins. 257 
 258 
2. THERAPEUTIC EFFICACY OF PHAGE LYTIC PROTEINS 259 
2.1. Animal models of infection 260 
After confirming the effectiveness of phage lytic proteins under in vitro conditions, it is 261 
essential to prove that they are also active in vivo. For this purpose, different animal models 262 
have been set up to mimic infections caused by S. aureus. These models allow testing the 263 
efficacy of therapeutic and prophylactic treatments of these infections with lytic proteins. 264 
(Table 1, Fig. 4A). Prophylaxis is particularly relevant with regard to S. aureus due to its 265 
presence in human skin, which constitutes a danger for patients with chronic diseases, 266 
immunocompromised patients and also for those subjected to surgery or hemodialysis. In 267 
some countries, nasal decolonization in high risk patients is currently carried out using 268 
mupirocin. However, effective removal of S. aureus from the nose requires the administration 269 
of several subsequent doses during five days, which raises the concern of mupirocin 270 
resistance development (46). In this context, several phage lytic proteins have been assayed 271 
in mice and rats to remove S. aureus from previously contaminated nostrils (28, 29, 43, 47 272 
and 48) (Table 1). Another potential prophylactic application of endolysins is skin 273 
decolonization in clinical patients, healthy workers or food handlers. The effectiveness of 274 
this measure has been evaluated by using skin models (porcine and murine) colonized by S. 275 
aureus where lytic proteins were applied by spraying or as an emollient ointment (35, 43) 276 
(Table 1).  277 
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Regarding infection treatment with phage lytic proteins, bacteremia has been the most widely 278 
studied, probably because it is the most dangerous stage in the S. aureus infection process. 279 
For example, induction of bacteremia in a mouse model by intraperitoneal injection of S. 280 
aureus (109 CFU/mouse) resulted in a mortality rate of 100% within 3 days. However, 281 
administration of a single intraperitoneal or intravenous injection of a solution containing a 282 
phage lytic protein significantly improved the survival of mice (17, 34, 37, 39 and 48-52) 283 
(Table 1). Moreover, this treatment significantly reduced the inflammatory response caused 284 
by bacteremia (49). Thus, animals treated with the lytic proteins exhibited normal levels of 285 
cytokines IFNγ, IL-4 and IL-6 mRNA. However, it must be noted that different lytic proteins 286 
displayed varying degrees of antimicrobial activity. For example, a study described that six 287 
lytic proteins (80a, phi11, LysK, lysostaphin, 2638A, and WMY) provided total protection 288 
from bacteremia-induced death, while Twort or phiSH2 only conferred partial protection 289 
(51). 290 
Phage lytic proteins can also be used for the treatment of mastitis in farm animals. To 291 
determine the feasibility of this application, a mouse model of mastitis was developed by 292 
infusion of 102 and 104 CFU into the mammary glands and subsequent treatment with several 293 
lytic proteins (53). This treatment led to a significant reduction in bacterial cell counts (Table 294 
1). To date, the results available regarding therapeutic trials with endolysins in cow udders 295 
are only preliminary but promising (54) (Table 1). Clearly, additional studies are needed 296 
before commercialization of these antimicrobials for application in cattle. Nonetheless, phage 297 
lytic proteins are bringing a positive outlook about the future of infection control in animal 298 
farming without contributing to the rise in antibiotic resistance.  299 
Finally, the application of endolysins for the treatment of ocular infections after surgery has 300 
also been explored with good results (55) (Table 1). All these data confirm the in vivo efficacy 301 
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of phage lytic proteins against S. aureus infections and suggest that lytic proteins do not 302 
trigger a significant immune response. Nevertheless, it is important to highlight that lytic 303 
activity varies greatly between proteins leading, in some cases, to the need to administer a 304 
high protein concentration. This may have consequences for the immune response and needs 305 
to be carefully examined on a case-by-case basis. 306 
 307 
2.2. Combination therapy with phage lytic proteins and other antimicrobials 308 
A strategy to improve the activity of phage lytic proteins is to combine them with other 309 
antimicrobials, which may lead to a synergistic effect against the target bacteria (17, 50, 56) 310 
(Table 1). This is the case of the lytic protein CF-301 and daptomycin, whose combination 311 
significantly increased survival from bacteremia in mice compared to the two antimicrobials 312 
used separately (56). Similarly, a combination of endolysin MR-10 and minocycline reverted 313 
systemic MRSA infection in mice, resulting in a 100% survival, and improved treatment of 314 
localized burn wound infections (50). Moreover, phage lytic proteins also displayed 315 
increased antimicrobial activity when combined with other proteins that hydrolyze 316 
peptidoglycan bonds. In a mouse model of mastitis, for instance, the chimeric protein λSA2-317 
E-LysK-SH3b showed a synergistic effect with lysostaphin against S. aureus (53) (Table 1). 318 
A clear advantage of combination therapy is that the synergistic effect would allow reducing 319 
the doses of each antimicrobial, thus limiting possible side effects. Moreover, this strategy 320 
could also theoretically reduce the likelihood of bacterial resistance development to 321 
antimicrobials with different mechanisms of action. 322 
 323 
2.3. Safety studies 324 
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Before a new drug can be used for therapeutic purposes in humans, several preclinical and 325 
clinical trials have to be performed. Preclinical studies include pharmacokinetics, ADME 326 
(absorption, distribution, metabolism and elimination) and other safety-related parameters, 327 
such as genotoxicity, mutagenicity, safety pharmacology and general toxicology (57). 328 
Among all these requirements, only few have already been met for S. aureus phage lytic 329 
proteins. For instance, the cytotoxicity of phage lytic protein P128 against two cell lines, 330 
HEp2 and Vero, was evaluated by using the MTT colorimetric assay to test any reduction in 331 
viability. No cytotoxic effect was observed even at the highest concentration tested (2.5 332 
mg/ml), which corresponds to more than 100×MIC of this protein against S. aureus (58). 333 
Additionally, the safety of phage lytic proteins was evaluated by studying whether they 334 
induced an inflammatory response and/or toxicity in animal models. A study showed that 335 
repeated treatment of mice with MV-L protein (500 U) via intraperitoneal injection triggered 336 
an immune response displayed as an increase in the level of antibodies against this protein 337 
(48). However, there were no apparent adverse effects for the animals or reduction in the 338 
antimicrobial activity of the protein (48). Moreover, repeated topical application of the lytic 339 
protein ClyS resulted in a low production of antibodies, and there was no inhibition of the 340 
lytic activity of the protein (17). 341 
Besides intraperitoneal injection and topical application, the toxicity of these proteins has 342 
been studied after single- and repeated-dose intravenous administration. Phage lytic protein 343 
SAL200 was intravenously administered (2-100 mg/kg) in mice and dogs, in general, with 344 
no abnormal findings. In the safety pharmacology studies, some abnormalities were observed 345 
in dogs after several doses (usually, when protein injection was performed for more than one 346 
week after the initial administration), which disappeared without damage to the 347 
cardiovascular, respiratory and central nervous systems (59). 348 
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Another interesting study carried out pharmacokinetic and safety tests on lytic proteins in 349 
monkeys. The maximum protein concentration in serum occurred immediately after 350 
administration, and ranged from 40.5 to 378.4 μg/ml, the mean residence time being 351 
approximately 1 hour. Another parameter that should be taken into consideration is the 352 
terminal half-life, defined as the time it takes for a substance to lose half of its pharmacologic 353 
activity. The values determined so far range from 0.4 to 5.3 h in males and 0.3 to 3.4 h in 354 
females after 1 day, whereas the terminal half-life ranged from 1.8 to 9.7 h in males and 1.2 355 
to 5.3 h in females after 5 days. This study also assessed the safety and tolerability of SAL200 356 
endolysin after intravenous administration of a single dose of 1-80 mg/kg/day for 6 days or 357 
multiple doses of 40 mg/kg/day for 5 days. The protein was well tolerated and no adverse 358 
effects were detected (60).  359 
Keeping all these results in mind, it seems that, in order to avoid any harmful effects, the 360 
dosing period for phage lytic proteins should be shorter than one week and the dose should 361 
be as low as possible within the efficacy range of the protein. In any case, further studies are 362 
still needed to totally ensure the safety of these proteins. 363 
 364 
2.4. Human clinical trials and product pipeline 365 
The use of phage lytic proteins for the treatment of human infections is by far the research 366 
field of greatest interest among all possible applications of these antimicrobials. Nonetheless, 367 
only one endolysin-based product is currently on the market. The Dutch biotech company 368 
Micreos has developed the first product containing an endolysin for human use, 369 
StaphefektTM, which is specific against S. aureus, including MRSA strains. This product is 370 
recommended for the early stages of S. aureus-related skin infections such as eczema, acne 371 
and rosacea, resulting in a reduction of inflammatory symptoms. Several formulations such 372 
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as creams and gels are currently commercialized under the Gladskin brand. It has been 373 
recently demonstrated that this product can successfully treat chronic and recurrent S. aureus-374 
related dermatoses without generating bacterial resistance after long-term daily therapy (61). 375 
Protein SAL200 has been recently assessed in the first-in-human phase 1 study of a phage 376 
endolysin-based drug to be administered intravenously. This work consisted of a single-377 
center, randomized, double-blind, placebo-controlled, single-dosing, and dose-escalating 378 
study of intravenous SAL200 administration in healthy male volunteers. No serious adverse 379 
effects were observed (62). 380 
The company ContraFect has recently started performing studies with CF-301, which is thus 381 
far the only endolysin to have entered human clinical trials in the USA. This protein has been 382 
specifically formulated for the treatment of S. aureus bloodstream infections, including 383 
endocarditis. Phase 1 clinical trials performed with healthy volunteers showed no adverse 384 
effects when the protein was administered intravenously 385 
(https://www.contrafect.com/pipeline/cf-301). The company is planning to initiate phase 2 386 
clinical trials with bacteremia patients in mid-2017 387 
(https://clinicaltrials.gov/ct2/show/NCT03163446#wrapper). 388 
The Indian company GangaGen is working with the lytic protein P128 (StaphTAME), which 389 
is intended for clearing nasal contamination of S. aureus in humans and is currently 390 
undergoing phase 2 clinical trials. The goal of these clinical trials is to determine the 391 
pharmacokinetics, immunogenicity, safety and tolerability in adult healthy volunteers. In a 392 
second study focused on assessing the safety and efficacy of this product, the protein was 393 
applied in the anterior nares of S. aureus carrier patients with chronic kidney disease who 394 
were on dialysis, and also in clinical patients in stable conditions 395 
(https://www.clinicaltrials.gov/ct2/show/NCT01746654?term=NCT01746654&rank=1). 396 
18 
 
The company is also planning to investigate the treatment of infected venous ulcers, since a 397 
preliminary study has already shown the safety of the protein for topical application 398 
(http://www.gangagen.com/clinical.html). 399 
Apart from the above-mentioned products, there are an important number of companies 400 
working on the development of phage-based products for medical applications 401 
(http://companies.phage.org/), some of which are already in different phases of clinical trials. 402 
Satisfactory results in these clinical trials might pave the way for research concerning new 403 
phage-derived proteins. 404 
 405 
3. S. aureus PHAGE LYTIC PROTEINS FOR THE IMPROVEMENT OF FOOD 406 
SAFETY 407 
The eradication of S. aureus from food environments (farm animals, industry surfaces, food 408 
handlers) (Fig. 4B) is indispensable to avoid contamination during processing of foodstuffs. 409 
Phage lytic proteins offer an alternative to classical biopreservation techniques (63-66) 410 
(Table 1) and contribute to the improvement of cleaning and disinfection procedures (see 411 
section 1.3). For instance, endolysin LysH5 was able to reduce S. aureus contamination in 412 
pasteurized milk down to undetectable levels (66). Moreover, it was shown that the ability of 413 
these proteins to remove pathogenic bacteria can be also improved by combination with other 414 
food additives such as essential oils and bacteriocins. For instance, the combination of 415 
endolysin LysSA97 and carvacrol reduced S. aureus contamination below the detection limit 416 
in both pasteurized skim milk and beef (63). Similarly, a synergistic effect between LysH5 417 
and the bacteriocin nisin was observed for the elimination of S. aureus in milk (64). Synergy 418 
between phage lytic proteins and other antimicrobials might be explained by an initial 419 
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weakening of the cell wall caused by the endolysin, which might facilitate the subsequent 420 
entry of the antibiotic or bacteriocin inside the bacterial cell (57). 421 
One important issue regarding the use of phage lytic proteins as biopreservatives is the effect 422 
on protein effectiveness of the physicochemical composition of the food matrix (67) and the 423 
strategy followed to deliver the protein into the food. One example of the latter is the use of 424 
starter cultures secreting endolysin to avoid contamination during the cheese manufacturing 425 
process. For example, Lactobacillus casei BL23 was engineered to deliver endolysin Lysdb 426 
to keep low levels of S. aureus contamination during production of cheese made from raw 427 
milk (68). 428 
Finally, the ability to detect very low concentrations of pathogenic bacteria in food is very 429 
relevant. In this regard, the CBDs from endolysins offer a good opportunity to create specific 430 
biosensors with high affinity and specificity. For example, the CBD from endolysin plyV12 431 
was used to obtain coated beads able to concentrate S. aureus cells by an inmunomagnetic 432 
separation method, the detection limit in milk being 4×103 CFU/mL in a testing time of 1.5 433 
h (69). 434 
 435 
4. CHALLENGES RELATED WITH THE COMMERCIALIZATION OF PHAGE 436 
LYTIC PROTEINS  437 
4.1. Large-scale production and formulation  438 
The widespread use of phage lytic proteins as antimicrobials would require large-scale 439 
production and proper purification of these proteins. In this context, the two main difficulties 440 
that must be overcome for translating from lab-scale to large-scale production are total 441 
production costs and safety issues. E. coli is the most common bacterium used for the 442 
expression of recombinant proteins since engineered strains are well known and there are 443 
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several molecular tools set up to work with this bacterium (70). Alternatively, high 444 
recombinant protein yields can be obtained using the methylotrophic yeast Pichia pastoris or 445 
some filamentous fungi (Aspergillus niger, Aspergillus oryzae, Aspergillus awamori, 446 
Chrysosporium lucknowense and A. chrysogenum) (71). 447 
To date, S. aureus endolysins have been mostly purified from E. coli, although it would be 448 
possible to assess other systems for their expression such as chloroplasts, with the advantages 449 
that they lack endotoxins and have a low cultivation cost. Indeed, endolysins Cpl-1 and Pal, 450 
specific against Streptococcus pneumoniae, were successfully expressed in chloroplasts of 451 
Chlamydomonas reinhardtii (72). Moreover, a platform for expressing an endolysin against 452 
Propionibacterium acnes in cyanobacteria has been recently patented (WO2016130024). 453 
The main advantages of microalgae are low cost, easy upscaling and the GRAS status of 454 
several species. Similarly, expression of recombinant proteins in plants is also a feasible 455 
alternative (73). 456 
An important issue regarding proteins intended for therapeutic applications is the purification 457 
degree. Proteins must be highly purified, especially those to be administered parenterally. 458 
Suspensions of these proteins have to be sterile products obtained after a high number of 459 
phases including centrifugation, ultrafiltration and chromatographic steps followed by 460 
sterilization by filtration and ultrafiltration. All these processes must be performed in clean 461 
areas (74). 462 
Finally, the formulation of therapeutic compounds containing lytic proteins requires 463 
overcoming some issues such as stability of the proteins under storage conditions, 464 
compatibility with the route of administration, and reduction of immunogenicity. Thus, 465 
several formulations include the presence of polymers to avoid protein aggregation. For 466 
instance, endolysin SAL-1 was formulated using calcium ions and Poloxamer 188 to prevent 467 
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aggregation and to maintain stability during long-term storage (34). Similarly, the stability 468 
of LysK was improved by forming complexes with polycationic polymers such as poly-L-469 
lysines. The interactions between the protein and the polymers can break down enzyme 470 
aggregates increasing the lytic activity and keeping full activity for at least 4 months (75). 471 
Similar results were obtained for the chimeric protein K-L (containing the LysK CHAP 472 
endopeptidase and amidase domains, as well as the lysostaphin glycyl-glycine endopeptidase 473 
domain), which showed increased stability in the presence of block-copolymers of poly-L-474 
glutamic acid and polyethylene glycol (76). On the other hand, incorporation of the lytic 475 
proteins into these polymers has the advantage of reducing their immunogenicity by 476 
hindering recognition by the immune system. This also prevents the inactivation of the 477 
protein caused in some cases by the polyethylene glycol used to reduce protein 478 
immunogenicity (76). 479 
Regarding the use of lytic proteins for topical applications, e.g. skin decolonization or 480 
disinfection, products can be formulated as an ointment using the commercially prepared 481 
Aquaphor. This formulation contains 41% petrolatum and other ingredients, such as mineral 482 
oil, ceresin, lanolin alcohol, panthenol, glycerin and bisabolol, and facilitates penetration of 483 
the phage lytic proteins into the skin (17). 484 
Finally, the administration of phage lytic proteins might require a system to control their 485 
delivery, such as nanoencapsulation. Release of these lytic proteins can then be triggered by 486 
pH, temperature, redox gradients, ultrasound intensity, light or electric pulses (77). Some 487 
successful results have been obtained with a cocktail containing proteins CHAPK and 488 
lysostaphin, which were encapsulated in nanoparticles of polyN-isopropylacrylamide 489 
(PNIPAM). The encapsulated proteins were released from the nanoparticles after a 490 
temperature increase, which simulated the conditions occurring in the skin during a S. aureus 491 
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infection (78). Overall, it seems that both production and formulation issues regarding phage 492 
lytic proteins can be easily overcome in the near future as has been previously shown for 493 
other types of therapeutic proteins.  494 
 495 
4.2.Regulatory framework  496 
To date, no phage lytic proteins have been accepted for human therapeutic use in Europe or 497 
the USA. The only exception is “Staphefekt” which is the first endolysin-based product 498 
approved in the EU under the status of “medical device” (Medical Devices Directive 499 
93/42/EC) (79). Aside from that, phage lytic proteins might be approved as “biological 500 
therapeutic proteins”, since they exhibit similar properties to other recombinant proteins that 501 
are already commercialized (80). Fortunately, this seems to be a shorter path than the one 502 
necessary for the authorization of bacteriophages, since there is no current legal framework 503 
that allows companies to place on the market bacteriophage products intended for human 504 
therapy (81). 505 
In the USA, FDA approvals for recombinant proteins have been consistently increasing since 506 
the 1980s. In general, biologics-based medicines have shorter authorization times than small 507 
molecules. For example, authorization of recombinant enzymes takes about 5.9 years versus 508 
8.3 years required for small molecules like antibiotics (82). 509 
Another recent trend is the approval of some biologics under the Orphan Drug Act, which 510 
was initially set up to encourage the development of drugs for rare diseases. Orphan drugs 511 
have some advantages for their commercialization as they have government financial 512 
incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory 513 
success (83). 514 
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It is important to note that the development of a new drug is estimated to cost 2.6 billion 515 
dollars and take at least a decade (84). This high cost, along with the short time of use of 516 
antibacterial agents by consumers, has made the development of these compounds less 517 
attractive to pharmaceutical industries. 518 
In the EU, the requirements for marketing medical products for human and veterinary use are 519 
regulated by Directive 2001/83/EC and Regulation (EC) Nº 726/2004. Within this 520 
framework, phage lytic proteins could be used in veterinary medicine for the treatment of S. 521 
aureus infections, such as mastitis in cows. The European Medicines Agency provides 522 
information for companies and individuals involved in developing and marketing medicines 523 
for veterinary use in the EU. Meanwhile, medical products without a marketing authorization 524 
could be used in patients with chronic diseases or when there is no other product available to 525 
treat the disease by means of the Compassionate Use Programs or Expanded Access 526 
Programs. Similarly, in the USA these products would be used under the Right to Try Act, 527 
which allows the treatment of patients who have been diagnosed with a terminal illness by 528 
using drugs that have successfully completed phase 1 of clinical investigation. 529 
When used as biopreservatives in the food industry, endolysins would be considered food 530 
additives and regulated as such. In this regard, Regulation EC 1333/2008 states that all 531 
additives in the EU must be authorized and listed with their respective conditions of use in 532 
the EU's positive list based on a safety assessment, technological need and ensuring that use 533 
of the additive will not mislead consumers. 534 
Last but not least, phage lytic proteins can also be used as disinfectants. In the EU, this would 535 
require approval under the Biocidal Products Regulation (BPR). The regulations concerning 536 
disinfectant approval in the USA are the Federal Insecticide, Fungicide, and Rodenticide Act 537 
(FIFRA) and the Medical Devices Amendment to the Food, Drug, and Cosmetic Act. These 538 
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two regulations are overseen by the Environment Protection Agency (EPA) and the Food and 539 
Drug Administration (FDA), respectively. FIFRA controls the commercialization of products 540 
for the disinfection of household and clinical contact surfaces, whereas the Medical Devices 541 
Amendment regulates the use of liquid chemical sterilants and high level disinfectants used 542 
for disinfection of clinical devices. The existing regulatory frameworks in both the EU and 543 
the USA ensure that products are efficacious, while exhibiting low toxicity and 544 
environmental risks. As a result, application for this type of approval generally requires a 545 
large number of studies, leading to high costs and long processing times. In this scenario, the 546 
commitment by the authorities to facilitate the process of approval of these products, as well 547 
as by the companies to invest in product development will be essential to place these new 548 
antimicrobials on the market.  549 
 550 
5. CONCLUDING REMARKS 551 
Today, infectious diseases remain an important cause of death, a situation that can only 552 
worsen with the increase in the antibiotic resistance of pathogenic bacteria. Hopefully, the 553 
lessons learned since the time of Fleming will allow us to search for new antimicrobials with 554 
improved characteristics against refractory bacteria. A set of phage lytic proteins active 555 
against S. aureus are being studied for their application in urgent medical scenarios such as 556 
bacteremia and endocarditis. The structure of these proteins offers many possibilities for their 557 
manipulation and data about protein-substrate interaction will be very valuable to understand 558 
their mechanisms of activity and specificity. An important issue that deserves further research 559 
is the potential development of bacterial resistance to phage lytic proteins. Although this does 560 
not seem particularly worrying at present, resistance selection under in vivo conditions still 561 
has to be studied. More efforts are also needed to find the most adequate combinations of 562 
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phage lytic proteins and other antimicrobials able to totally remove S. aureus biofilms from 563 
both clinical and food environments. The adaptive responses of S. aureus biofilms exposed 564 
to phage proteins and their consequences regarding virulence and resistance should also be 565 
elucidated. Overall, it can be concluded that there is evidence of the effectiveness of phage 566 
lytic proteins as therapeutics in animal models of disease, and as food biopreservatives, 567 
although efficacy in the latter application depends on the physicochemical properties of the 568 
food. On the basis of these successful results, preclinical studies and clinical trials are 569 
currently under way. However, it is clear that further data about drug safety are still 570 
necessary. Nonetheless, the support of pharmaceutical companies through investment in 571 
these antimicrobials is essential to definitely boost this research. In turn, this cannot be 572 
achieved without an incentive from health authorities together with a new legal framework 573 
for authorization of these products. 574 
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TABLES 848 
Table 1. Phage lytic proteins against S. aureus and their most relevant properties. 849 
Application 
 
Lytic 
protein 
Origin Results Reference 
Prophylaxis P128 CHAP domain 
(TAME phage 
K)+SH3b 
(lysostaphin) 
Rat nares: 4 log reduction after 
treatment with 15 µg of protein. 
(28) 
 
Prophylaxis L-K Catalytic domain 
(LysK)+ 
lysostaphin 
Mice nares: 98% reduction after 
treatment with 200 µg of protein. 
(29) 
Prophylaxis 
 
CHAPK CHAP domain 
(LysK) 
Mice nares: 2-log reduction after 
1 h of treatment with 925 μg of 
protein. 
Porcine skin: 99% reduction 
(colonized by 2.5×105 CFU/cm2) 
after 30 min of treatment. 
(47, 35) 
Prophylaxis, 
bacteremia 
ClyS Catalytic domain 
(phage Twort)+ 
CBD (phiNM3) 
Mice nares: 2-log reduction after 
treatment with 960 µg of protein. 
Mouse skin: 3 log reduction. 
Intraperitoneal injection (1 mg) at 
3 h post-infection resulted in 88% 
survival. 
Combination with vancomycin 
and oxacillin resulted in a 100% 
survival. 
(43, 17) 
Prophylaxis, 
bacteremia 
MV-L phage MV-L Mice nares: 2×109 CFU reduction 
after treatment with 310 U of 
protein. 
Intraperitoneal injection (500 U) 
60 min after infection resulted in 
60% survival. 
(48) 
Bacteremia SAL-1 
(SAL200) 
phage SAP-1 Mice model: Intravenous 
administration (25 mg/kg) 
resulted in 100% survival. 
(34) 
Bacteremia LysGH15 phage GH15 Intraperitoneal injection (50 µg) 1 
h after infection resulted in 100% 
survival. 
(49) 
Bacteremia Phi11, 80a, 
LysK, 2638A, 
and WMY 
Twort, phiSH2 
Phage phi11 
Phage phi80a 
Phage K 
Phage 2638A 
Phage WMY 
 
Mice model: Intraperitoneal 
injection (200 µg) 30 min post-
infection showed a 100% survival 
for phi11, 80a, LysK, 2638A and 
WMY, and 50-60% for Twort and 
phiSH2. 
(51) 
Bacteremia P-27/HP Endolysin from 
phage P-27/HP 
Mice model: Intraperitoneal 
injection (250 µg) after 24 h of 
infection resulted in a 99.9% 
reduction in CFU counts in 
spleens. 
(52) 
Bacteremia CF-301 Endolysin 
Streptococcus suis 
prophage 
 
Combination of CF-301 (1.25 
mg/kg) and daptomycin 4 h after 
infection yielded a 73% of 
survival. 
(56) 
39 
 
Bacteremia, 
burn infection 
ClyF CBD domain 
(PlySs2)+catalytic 
domain (Ply187) 
Intraperitoneal injection (50 
mg/kg) at 3 h post-infection 
resulted in 100% survival. 
Bacterial reduction of 1.5-3.3 
log10 in the treatment of burn 
infection with 0.1 mg at 24 h post 
infection. 
(37) 
Disinfection, 
bacteremia 
MR-10 phage MR-10 Biofilm reduction after sequential 
treatment with minocycline (4 
μg/ml) for 3 h followed by 
treatment with endolysin MR-10 
(18-36 μg/ml) for 16 h. 
Combination of MR-10 and 
minocycline resulting in a 100% 
survival. 
(39, 50) 
Endophthalmitis Ply187 CHAP domain 
(Ply187)+SH3b 
(LysK) 
Mice model: Intravitreal injection 
1-2 log reduction at 6 h and 12 h 
after infection. 
(55) 
Mastitis Trx-Sa1 phage IME-SA1 Cows: Reduction of bacterial 
counts to undetectable levels after 
3 days. 
(54) 
Mastitis λSA2-E-Lyso-
SH3b and 
λSA2-E-
LysK-SH3b 
Endopeptidase 
domain 
(streptococcal SA2 
endolysin)+CBD 
(lysostaphin or 
LysK) 
Mice model: 0.63 and 0.81 log 
units reduction after gland 
infusion (25 µg). Synergistic 
effect with lysostaphin. 
(53) 
Dermatoses Staphefekt 
SA.100 
Commercial 
endolysin 
Human: Reduction of 
inflammatory symptoms of 
osteosarcoma, impetigo and 
folliculitis after 2 weeks 
application twice a day. 
(61) 
Food 
preservation 
LysSA97 phage SA97 Beef and milk: 0.8±0.2 log 
CFU/ml reduction. Reduction of 
4.5±0.2 log CFU/ml when 
combined with carvacrol. 
(63) 
Food 
preservation 
HydH5, 
HydH5Lyso, 
HydH5SH3b, 
CHAPSH3b 
VAPGHs-derived 
proteins (phage 
phiIPLA88) 
Milk: Undetectable bacteria (104 
CFU/ml) after 6 h of incubation at 
37ºC. 
(65) 
Disinfection, 
food 
preservation 
LysH5 phage phiIPLA88 Biofilm removal after treatment 
with 0.15 µM for 6 h, followed by 
a second treatment for 12 h. 
Pasteurized milk: Undetectable 
bacteria (106 CFU/ml) after 
treatment with 88 μg/ml for 4 h. 
Synergistic effect with nisin. 
(38, 64, 
66) 
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FIGURES 852 
Figure 1. A) Bacteriophage lytic cycle: 1. Adsorption of phage to the bacterium; 2. Injection 853 
of genetic material into the cytoplasm;. 3. Replication of phage genetic material. 4. Synthesis 854 
of phage components; 5. Assembly of new phage particles; 6. Bacterial lysis and release of 855 
phage particles. B) Role of phage lytic proteins in the phage life cycle. VAPGHs favor the 856 
injection of phage genetic material into the cytoplasm by the formation of a hole in the cell 857 
wall. Endolysins and holins are produced at the end of the life cycle. Holins form a pore into 858 
the bacterial membrane allowing the endolysin to reach the peptidoglycan.  859 
Figure 2. Structure and enzymatic activity of phage lytic proteins against S. aureus 860 
peptidoglycan. A) The typical modular structure of phage lytic proteins (endolysins and 861 
VAPGHs) is represented by the catalytic domains and the cell wall binding domains (CBDs). 862 
B) The structure of S. aureus peptidoglycan is shown and the enzymatic activity of the 863 
proteins indicated with an arrow and a number. 1: N-acetylmuramoyl-L-alanine amidase; 2: 864 
interpeptide bridge endopeptidase; 3: L-alanoyl-D-glutamate endopeptidase; 4: N-acetyl-β-865 
D-muramidase; 5: transglycosylase; 6) N-acetyl-β-D-glucosaminidase. 866 
Figure 3. Schematic representation of the domain shuffling strategy to obtain chimeric 867 
proteins from two phage lytic proteins. C1, C2 and C3 represent catalytic domains while 868 
CBD1 and CBD2 represent different cell wall binding domains. 869 
Figure 4. Current applications of S. aureus phage lytic proteins in A) human and animal 870 
therapy and B) improvement of food safety. 871 
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